BidSi6 and BidEL isoforms as a potential marker for predicting colorectal adenomatous polyps

Flora Forouzesh1*, Fatemeh Sadat Kia1 and Ehsan Nazemalhosseini-Mojarrad2

Abstract
Background: As a well-known protein, Bid links the extrinsic and intrinsic apoptotic pathways and plays important roles in cell proliferation. In this study, we evaluated the expression of two isoforms of the Bid gene (BidSi6 and BidEL) in colorectal adenomatous polyps as a biomarker and investigated the relationship between their expression levels with clinicopathological factors.

Methods: The expression of BidSi6 and BidEL isoforms in 22 pairs of Adenomatous polyps and adjust non-polyp tissues was measured by qReal-Time PCR and compared with 10 normal colon tissues. ROC curve was performed to examine the diagnostic capacity. Also, sequencing was performed for molecular identification of BidSi6 isoform in adenomatous polyp.

Results: Our results showed that BidSi6 and BidEL isoforms were significantly overexpressed in Adenomatous polyps and non-polyp adjacent tissues from the same patients compared to that in normal colon tissues, but there was no significant expression between polyps and adjust non-polyp tissues. There were no significant correlations between the expression of two isoforms and other features of clinicopathology. The area under the curve of BidSi6 and BidEL isoforms indicated powerful diagnostic capability. The phylogenetic tree was constructed based on the sequence of idSi6 isoform, and the results showed that adenomatous polyp tissue and adjust non-polyp tissue were separated from healthy colorectal tissue and reference sequence (EU678292).

Conclusions: These findings suggest that BidSi6 and BidEL isoforms can be used as new potential biomarkers in adenomatous polyps.

Keywords: Adenomatous polyposis, Bid, Isoforms, Prognosis, Colorectal cancer

Background
Colorectal cancer (CRC) occurs mainly in non-cancerous adenomas or polyps that form on the colon and rectum. Epithelial polyps are classified as adenomatous or hyperplastic (HP), and adenomatous polyps are considered progressive lesions [1]. Evidence indicates that alternative splicing plays a crucial role in cancer. More than 1500 splice events in 885 genes were reported and most of them enriched CRC-associated pathways and functions [2]. These events affect the carcinogenesis of colon cancer [3]. Alternative splicing may be used as biological markers of prognosis and diagnosis [4].

The Bcl-2 family greatly influences the progression of cancer and regulators of cell death, hence affecting the sensitivity of tumor cells to radiotherapy.

*Correspondence: f8forouzesh@gmail.com; forouzesh@iautmuc.ac.ir
1 Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, P. O. Box: 193951495, Tehran, Iran
Full list of author information is available at the end of the article
Bid is a member of Bcl-2 family protein and impacts several pathways of apoptosis by incorporating signals in mitochondrial apoptosis [5, 6]. Growing evidence supports that Bid has critical roles for stress-response [7, 8]. Alternative splicing in the Bid gene might affect the function of the gene. The isoforms have differences in expression, functional effects and cellular localization. There are three Bid splice variants and tissue distribution of three proteins is exclusive and distinct. Most importantly, they modulate cellular apoptosis differently [9]. BidS isoform has the N-terminal inhibitory fragment of Bid and does not have the BH3 domain. BidL (full-length) which denominated BidEL has an additional N-terminal sequence. BidES isoform has only the downstream of the BH3 domain of the Bid sequence. BidS functions as an inhibitor of apoptosis, whereas BidEL induces apoptosis. BidES induces apoptosis but is also able to partially inhibit the pro-apoptotic function of truncated Bid [6].

Previous studies indicate that the balance between gene variants seems to regulate cellular proliferation, differentiation and apoptosis, and the inhibition of tumor growth. Obtaining splicing patterns in malignancies will provide novel prognostic and diagnostic biomarkers and introduce novel treatments in cancer therapeutic targets. In other words, the splice variants that are involved in tumor formation and development can be targeted by molecular therapies that are close to clinical usage. These therapies include modifying the splicing events by the use of oligonucleotide-mediated therapies, targeted protein therapy by small peptides of protein isoforms or splicing regulators, and reprogramming of RNAs to modify alternative splicing patterns [10–12].

The conventional therapies of CRC are surgery, chemotherapy, and radiotherapy. Also, the combination of chemotherapy and immunotherapy targets the dysregulated proteins [13]. Colonoscopy is a main diagnostic tool to screen for CRC since it can detect and effectively remove pro-malignant and malignant lesions. Approximately all gastroenterology and cancer societies recommended this test, following a positive fecal occult blood test, to be performed every 10 years in people of average risk starting from the age of 50 [14]. To help clinicians to optimize their function, it is important to nominate more effective tools that improve early diagnosis and predict the most likely progress of the disease and response to chemotherapy. Thus, they mitigate both the morbidity and mortality of their patients. So, researchers are now developing novel therapeutic approaches for the treatment of CRC by detecting important key biomarkers to understand their molecular mechanisms [15].

In this study, we investigate the expression of two isoforms of Bid (BidEL and BidSi6) transcript in adenomatous polyps and adjust non-polyp tissues from the same patient compared to healthy controls. The study objective is also to assess the expressions of isoforms of Bid in adenoma depending on the sex and age of patients, tumor location in the colon and rectum, and the effect of BidEL and BidSi6 expression in adenomatous polyps.

**Materials and methods**

**Patients**

The sample was chosen from the cases with adenomatous polyps that were referred to the Taleghani Hospital, Tehran, Iran, from April 2014 to May 2016. We collected 22 adenomatous polyps and adjacent non-polyps tissues and 10 healthy colorectal tissue as controls. Biopsy samples of the adenoma polyp of patients were confirmed by a pathologist. The patients had not received any chemotherapy before the surgery. The patients’ age ranged from 28 to 75 years with a mean ±SE of 52. The healthy controls were selected from biopsy samples with a disease-free health as confirmed by a pathologist. The patients that participated in this study provided signed informed consent by the Research and Ethical Committee of Taleghani Hospital. The information about the clinicopathological characteristics of all contributors was retaken from medical records and questionnaires (Table 1).

**Isolation of total RNA**

Total-RNA from tissues was extracted using the Yekta Tajhiz Azma kit (Iran, Tehran) according to the manufacturer’s instructions. Quantification of total RNA was determined through spectrophotometry (Thermo Nanodrap).

**Reverse transcription polymerase chain reaction**

cDNA synthesis was performed with TaKaRa kit (Cat No.RR037A, Tokyo, Japan) according to the
Real-Time quantitative polymerase chain reaction

Quantitative Real-Time PCR was performed using the SYBR Premix Ex Taq II kit (TaKaRa Biotechnology, Japan) in a 7500 Real-Time PCR System (Applied Biosystems, CA, USA). Two pairs of gene-specific primers (BidSi6 and BidEL) were designed using the Gene-runner version 3.05 software. The BidSi6 real-time PCR primers were 5'- AATAGAGGCAGG GCCGTC -3' and 5'- TCA GTCCCTCCCTC TCGC-3', producing a 157-bp PCR amplicon. The BidEL real-time PCR primers were 5'- AAGTTGCTGNGCTGCAAAG -3' and 5'- CCA GTG GCCAGAC AGT CCG -3', producing a 138-bp PCR amplicon (Additional file 1). The Beta-2-microglobulin real-time PCR primers were 5'- TGCTGTCTCCCATGTT TGATGATCT -3' and 5'- TCTCTGCTCCCACCTCT AAG -3', producing a 86-bp PCR amplicon.

The reaction mixture contained 1 µl of each primer (10 pmol), 5 µl of cDNA, 10 µl of SYBR Premix Ex Taq II (2x), 0.3 µl of ROX Reference Dye (50x) and 3.7 µl of sterile distilled water, in a final reaction volume of 20 µl. The cycling conditions were as follows: 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. Beta-2-microglobulin was used as an internal control to normalize the PCRs for the amount of RNA added to the reverse transcription reactions. The relative expression levels of BidSi6 mRNA and BidEL mRNA were calculated by the 2^-ΔΔCt method. Each real-time PCR reaction was performed in triplicate to evaluate the reproducibility of data.

Sequencing of BidSi6 isoform

Conventional PCR

For sequencing, other reverse BidSi6 primers were designed using the Gene runner (version 3.05) software at the junction of the exon to exon. The following factors were considered in the design of the primer: (1) primer-dimerization does not form. (2) BidSi6 primers must amplify a unique region as the primers itself is unique. (3) BidSi6 primers in the same direction must be non-overlapping. (4) The primer selection must be physicochemically appropriate, as described by GC content, melting temperature and other parameters. The sequence of Forward BidSi6 primers is 5'- AATAGAGGCAGG GCCGTC -3' and Reverse BidSi6 primers is 5'- TCA GTCCCTCCCTC TCGC-3'. The size of PCR fragment is 777 base pair.

For subsequent PCR analysis, 1 µl of the first-strand cDNA was used for PCR amplification in a reaction volume of 25 µl. All PCR reactions PCR were performed using the Sinaclone kit (Tehran, Iran). The following PCR conditions for BidSi6 gene were used: initial denaturation performed at 95 °C for 5 min, followed by 40 cycles where denaturation occurred at 94 °C for 45 s with an annealing temperature of 62 °C for 40 s. Elongation was performed at 72 °C for 30 s and the final extension at 72 °C for 5 min. Negative control with primers was used for all the PCR amplifications. Then, the PCR products were separated in 1.5% agarose gel electrophoresis and visualized under UV light (Vilber Iourmat, UK).

Nucleotide sequencing

The positive results in electrophoresis were selected for sequencing. Distinct gel bands were purified with a gel extraction kit (Qiagen- Germany). Analysis of sequences was performed using the ChromasPro (version 2.6.5) software. All the nucleotide sequences were aligned with each other. According to the identity percentage and query coverage parameter, the reference sequences were downloaded from the GenBank database using the Basic Local Alignment Search Tool (BLAST), Clustal omega (https://www.ebi.ac.uk/Tools/msa/clustalo/), and other programs available in NCBI site (National Center for Biotechnology Information) to determine the isoforms of BidSi6.

Nucleotide sequence accession numbers

If the isoform BidSi6 obtained in this study with the cutoff values above 95% in nucleotide and amino acid sequence similarity was identical to those published in GenBank, these sequences were identified to be known isoforms and would be registered in the GenBank and given the first published name.

Statistical analysis

All the results were recorded as means± standard deviation and the statistical analyses were conducted using the GraphPad Prism version 3.05 Software (GraphPad Software, CA, USA). Student’s t-test and one-way analysis of variance (ANOVA) were used. To assess the diagnostic performance of BidSi6 and BidEL, the Receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were constructed. P<0.05 was considered statistically significant.
Results

BidSi6 mRNA expression in adenoma polyp tissues

BidSi6 isoform expressions were measured in 22 pairs of adenomatous polyp tissues and adjust non-polyp tissues from the same patient, and the expression values obtained were compared between the paired samples and healthy colorectal tissues. We found that BidSi6 isoform expression increased significantly in both adenomatous polyp tissues and the paired adjust non-polyp tissues compared with the control group (healthy colorectal tissues) ($P = 0.0007$) (Fig. 1A). BidSi6 was down-regulated in adenomatous polyp tissue samples compared to adjust non-polyp, but the difference in expression between them was not statistically significant ($P = 0.668$).

Correlation of BidSi6 expression with clinicopathological features of patients with adenomatous polyp

We compared the BidSi6 expression with clinicopathological features of adenomatous polyp between these groups. According to the location of the adenomatous polyp, the study group was divided into five subgroups: patients with polyps located in ascending colon, transverse colon, descending colon, sigmoid and rectum. Polyps were seen in ascending colon, transverse colon, descending colon and rectum showed increased expression compared to the control group. However, in the sigmoid section of the intestine and rectum, there was no change in expression of the BidSi6 gene compared to the control group (healthy colorectal tissue) (Fig. 1B). We found that the expression of BidSi6 in descending colon location was higher than other polyp’s location.

We compared the mRNA levels of BidSi6 between male and female patients. The expression of the BidSi6 isoform
in the male group was higher than in the female group, but there was no significant difference between them \((P=0.497)\) (Fig. 1C).

To better understand the relationship between BidSi6 expression and patient age, patients were divided into two groups \((\leq 50\) years and \(> 50\) years). No significant difference was observed between \(\leq 50\)-year and \(> 50\)-year groups \((P=0.969)\) (Fig. 1D).

**BidEL mRNA expression in adenomatous polyp tissues**

Expression of BidEL was significantly higher in adenomatous polyp tissues and adjacent non-polyp tissues than in control groups (healthy colorectal tissues) \((P=0.035)\). Also, BidEL was down-regulated in adenomatous polyp tissue samples in comparison with adjacent non-polyp tissues, but the difference in expression between adenomatous polyp tissue samples and adjacent non-polyp tissues samples was not statistically significant.

**Correlation of BidEL expression with clinicopathological features of patients with adenomatous polyp**

The relationships between BidEL expression and clinicopathological variables for an adenomatous polyp in 22 patients were considered. There were no statistically significant associations between BidEL expression and location of polyps (ascending colon, transverse colon, descending colon, sigmoid colon and rectum), although the expression of BidEL in the transverse colon was higher than other polyp’s location (Fig. 2B).

The expression of BidEL isoform in the male group was higher than in the female group but statistically not significant at \(P=0.526\) (Fig. 2C). Also, no correlation was observed between BidEL expression and age \((\leq 50\)-year and \(> 50\)-year groups) \((P=0.526)\) (Fig. 2D).

![Fig. 2](image-url)
The expression of Bidsi6 isoform and BidEL isoform were compared in 22 polyps of patients. The expression of the Bidsi6 isoform was higher than the BidEL isoform but statistically not significant at \( P = 0.146 \) (Fig. 3).

**Diagnostic potential of Bidsi6 and BidEL isoform**

ROC curve analysis was performed to identify the diagnostic value of Bidsi6 and BidEL isoform patients with adenomatous polyps (Fig. 4). The AUC value of the ROC curve of the Bidsi6 isoform was 0.8727 and 95% confidence interval (CI) was 0.7255–1. The AUC value of the ROC curve of the BidEL isoform was 0.8955 and the 95% confidence interval (CI) was 0.7499–1. These results suggested the potential diagnostic roles of these two isoforms in patients with adenomatous polyps.

**Molecular identification and sequence analysis of the Bidsi6 isoform in adenomatous polyp**

Conventional PCR was carried out with Bidsi6 primers on adenomatous polyp tissues and adjust non-polyp tissues from the same patients and healthy colorectal tissue. Samples were shown to have PCR amplified fragments with around 777 bp for Bidsi6 (Fig. 5). Three PCR positive results of adenomatous polyp tissue, adjust non-polyp tissue from the same patient and healthy colorectal tissue in electrophoresis were selected for sequencing. Sequencing was performed with forward and reverse primers of Bidsi6. The sequences were analyzed using the ChromasPro (version 2.6.5) software. All the nucleotide sequences were aligned with each other. According to the identity percentage and query coverage parameter, the

---

**Fig. 3** The expression level of Bidsi6 and BidEL isoform in polyp tissues. The expression of the Bidsi6 isoform was higher than the BidEL isoform in polyps but this difference is not significant \( (P = 0.146) \)

**Fig. 4** ROC curve analysis of Bidsi6 and BidEL isoforms, based on the area under the curve (AUC) in adenomatous polyps to examine the validity of Bidsi6 gene expression in discriminating polyps and non-polyps of the colon tissues. **A**. ROC curve analysis of Bidsi6 isoforms expression (AUC: 0.8727, AUC CI 0.7255–1, p-value: 0.0280). **B**. ROC curve analysis of BidEL isoforms expression (AUC: 0.8955, AUC CI 0.7499–1, p-value: 0.0139)
reference sequences were downloaded from the GenBank database using the Basic Local Alignment Search Tool (BLAST) (accession number of the reference sequence is EU678292) and Claustal omega (https://www.ebi.ac.uk/Tools/msa/clustalo/), and other programs available in NCBI site (National Center for Biotechnology Information) to determine the isoforms of BidSi6 (Fig. 6A). Phylogenetic tree construction revealed that all the samples stand in a single clade (Fig. 6B).

Comparison of BidSi6 sequence in adenomatous polyp tissue with BidSi6 reference sequence (EU678292)
The comparison of BidSi6 sequences between human adenomatous polyp tissue and reference sequences (EU678292) using the BLAST tool reveals 99% Identities. We found three point mutations in BidSi6 sequences in polyp tissue compared with the reference sequence (EU678292). There are in positions 591 (A to G), 699 (C to T) and 993 (T to C) (Fig. 7), which did not change the amino acid sequence.

Nucleotide and amino acid sequences related to BidSi6 isoform in adenomatous polyp tissue were submitted to GenBank and could be accessed through the following accession numbers: MG957990 and AVP50013 respectively in the European Molecular Biology Laboratory and DNA Data Bank of Japan.

Comparison of BidSi6 sequence in adjust non-polyp tissue with BidSi6 reference sequence (EU678292)
The comparisons of BidSi6 sequences between adjust non-polyp tissue from the same patient mentioned above and reference sequences (EU678292) using the BLAST tool reveal 99% Identities. The alignment of the two sequences reveals two point mutations in BidSi6 sequences in adjust tissue as compared with the reference sequence (EU678292). There are in the same position 591 (A to G) and position 699 (C to T) (Fig. 8) like adenomatous polyp tissue. In this study, the size of the sequenced fragment of BidSi6 isoform in adenomatous polyp tissue and adjust non-polyp tissue from the same patient were 728 bp and 548 bp respectively. Thus, the third point mutation (position 993) in the adjust tissue was not reported. Nucleotide and amino acid sequences related to BidSi6 isoform in adjust non-polyp tissue were submitted to GenBank with the accession numbers MG957991 and AVP50014 respectively in the European Molecular Biology Laboratory and DNA Data Bank of Japan.

Comparison of BidSi6 sequence in healthy colorectal tissue with BidSi6 reference sequence (EU678292)
The comparisons of BidSi6 sequences between healthy colorectal tissue and reference sequences (EU678292) using the BLAST tool reveals 100% Identities, and no mutations were observed in the BidSi6 sequence of healthy colorectal tissue. Nucleotide and amino acid sequences related to BidSi6 isoform in healthy colorectal tissue were submitted to GenBank, which can be accessed through the following accession numbers: MH121045 and AWQ38328 respectively in the European Molecular Biology Laboratory and DNA Data Bank of Japan.

Discussion
In the present study, we considered the expression of two isoforms of the Bid gene in adenomatous polyps and adjust non-polyp tissues from the same patient with healthy colorectal tissue. In the second part of our study, we performed molecular identification and sequence analysis of the BidSi6 isoform in the adenomatous polyp, adjust non-polyp tissue and healthy colorectal tissue. More than 95% of colorectal cancers are assumed to have a premalignant adenomatous polyp phase. Approximately there is a 95% increase in colorectal cancers within adenomatous polyps. These lesions with dysplastic epithelium have a great potential for malignancy [16]. During tumorigenesis, cells produce aberrant proteins with inserted, altered or missing functional domains [17]. There is accumulating evidence that aberrant alternative splicing leads to the development and progression of malignancy [18]. Also, we considered the correlation of BidSi6 and BidEL expression with clinicopathological features and its potential as diagnostic and prognostic markers was examined. Aberrant RNA splicing is more effective in
drug therapy resistance than previously thought [19]. However, novel classes of biomarkers with high specificity, sensitivity, and efficiency are required for the prognosis and diagnosis of adenomatous polyps.

The bid has a unique role in connecting the activation of the extrinsic apoptosis pathway to the activation of the intrinsic pathway. In addition, Bid has an important role in regulating cell cycle arrest [7, 20].

Alternative splicing introduces another way of control to the gene expression pathways because it produces protein isoforms with approximately different functions [21, 22]. Alternative splicing Bid gene, effects on the endogenous protein level and display segregated functions and cellular localization [9]. Functional Consequences of Alternative Splicing is altered apoptotic potential. Each Bid isoform has behaved differently to change the activity of Bid following cleavage and activation [23–27]. BidEL induces apoptosis, whereas BidS inhibits the apoptotic effects of tBid and abrogates apoptosis mediated by Fas [7, 28]. The features of the BidSi6 isoforms are similar to that of BidS isoforms with an inhibitory BH3 domain that could suppress apoptosis. We found significantly high expression of BidSi6 and BidEL isoforms at mRNA levels in adenomatous polyps and adjust non-polyp tissues from the same patient compared with healthy group, but there was no statistically significant difference between their expression in adenomatous polyps and adjust non-polyp tissues.

---

**Fig. 6** A CLUSTAL O (1.2.4) multiple sequence alignment based on the BidSi6 isoform sequence of human adenomatous polyp tissue, adjust non-polyp tissue from the same patient, and healthy colorectal tissue. B Phylogenetic tree constructed based on the BidSi6 isoform sequence in human adenomatous polyp tissue, adjust non-polyp tissue from the same patient, healthy colorectal tissue, and reference sequence (EU678292). TS is the code of a sample.
Polyp-TS       TTGGGTTGTGTGGTGTGAGCCATGAAGCCGCTGCCAGGTTTGTACCTCAGGCGTGGTCGT 414
Adjust-TS      TTGGGTTGTGTGGTGTGAGCCATGAAGCCGCTGCCAGGTTTGTACCTCAGGCGTGGTCGT 375
Healthy        TTGGGTTGTGTGGTGTGAGCCATGAAGCCGCTGCCAGGCTTGTACCTCAGGCGTGGTCGT 414
EU678292       TTGGGTTGTGTGGTGTGAGCCATGAAGCCGCTGCCAGGCTTGTACCTCAGGCGTGGTCGT 720

Polyp-TS       GATGCCCCAGCTTCACCGGCCCTGCCTGTGGGGACGTGGTGCCTGTGTGCGGGAGCCTGG 474
Adjust-TS      GATGCCCCAGCTTCACCGGCCCTGCCTGTGGGGACGTGGTGCCTGTGTGCGGGAGCCTGG 435
Healthy        GATGCCCCAGCTTCACCGGCCCTGCCTGTGGGGACGTGGTGCCTGTGTGCGGGAGCCTGG 474
EU678292       GATGCCCCAGCTTCACCGGCCCTGCCTGTGGGGACGTGGTGCCTGTGTGCGGGAGCCTGG 780

Polyp-TS       GCCTCAGCCGAGGCCCTGAGCTCCGGCACTGCCCAGAACCCAGCTCAGCGCTGGTACTCA 534
Adjust-TS      GCCTCAGCCGAGGCCCTGAGCTCCGGCACTGCCCAGAACCCAGCTCAGCGCTGGTACTCA 495
Healthy        GCCTCAGCCGAGGCCCTGAGCTCCGGCACTGCCCAGAACCCAGCTCAGCGCTGGTACTCA 534
EU678292       GCCTCAGCCGAGGCCCTGAGCTCCGGCACTGCCCAGAACCCAGCTCAGCGCTGGTACTCA 840

Polyp-TS       GCCCGCCCGCTGTGGCCCTGGTGGAGTGGAGCACGTGCCCAGTGGGGGCTGGCCTTGTCC 594
Adjust-TS      GCCCGCCCGCTGTGGCCCTGGTGGAGTGGAGCACGTGCCCAGTGGGGGCTGGCCTTGTCC 548
Healthy        GCCCGCCCGCTGTGGCCCTGGTGGAGTGGAGCACGTGCCCAGTGGGGGCTGGCCTTGTCC 594
EU678292       GCCCGCCCGCTGTGGCCCTGGTGGAGTGGAGCACGTGCCCAGTGGGGGCTGGCCTTGTCC 900

Polyp-TS       CATCGCGGACCTGTCCTTTCCCGGGGCAGGGTGGTGTGGGAGAGGGTATCAGGGACATTT 654
Adjust-TS      ------------------------------------------------------------ 548
Healthy        CATCGC------------------------------------------------------ 600
EU678292       CATCGCGGACCTGTCCTTTCCCGGGGCAGGGTGGTGTGGGAGAGGGTATCAGGGACATTT 960

Polyp-TS       TCTGAGTCTGCTCTGTCTCTGCCGCCCCTGCCCGAACACAGATTCTGAAAGTCAAGAAGA 714
Adjust-TS      ------------------------------------------------------------ 548
Healthy        ------------------------------------------------------------ 600
EU678292       TCTGAGTCTGCTCTGTCTCTGCCGCCCCTGCCCGAACACAGATTCTGAAAGTCAAGAAGA 1020

Polyp-TS       CATCATCCGGAATA---------------------------------------------- 728
Adjust-TS      ------------------------------------------------------------ 548
Healthy        ------------------------------------------------------------ 600
EU678292       CATCATCCGGAATA---------------------------------------------- 1080

Fig. 6 continued
Renshaw et al. showed that the expression of BidEL and BidS mRNA level increased during myeloid differentiation. This indicates that BidEL and BidS act differently in the adjustment of the dead cells in developing myeloid cells [9]. Several investigators have suggested that the tBid-N sequence, when expressed separately, can inhibit the pro-apoptotic activity of the tBid-C fragment [9, 29]. Collectively, these data offer a crucial inhibitory effect of the N-terminus of Bid upon the C-terminal pro-apoptotic function during Bid cleavage. Elevated expression of Bid has been reported in some tumors, such as colon carcinomas, gliomas and prostate cancers. Higher levels of Bid were also found in lymphomas with more advanced histology and advanced prostate cancers indicating higher expression compared to earlier stage tumors [6]. Higher levels of Bid may indicate other compensatory defects in apoptosis pathways that help tumor cells to tolerate elevated levels of this protein [28].

Also in the present study, we found that BidSi6 and BidEL isoforms have a relatively high diagnostic efficiency with an AUC of 0.8727 and AUC of 0.8955 respectively for adenomatous polyps. However, BidSi6 and BidEL isoforms were identified as a marker for screening, and they showed high specificity and sensitivity for diagnosis. Moreover, our results demonstrate that the expression of Bidsi6 isoform was higher than BidEL isoform in polyp tissues but statistically not significant. Based on our results, we propose that the
upregulation of BidSi6 in patients with Adenoma polyps eliminated the pro-apoptotic effects of tBid and inhibits apoptosis mediated by Fas, which can lead to dysplasia. The presence of pro-apoptotic Bid can also determine tumor cell susceptibility to extrinsic apoptotic stimuli [30] suggesting that both quantity and ratio of Bid splice variants can strongly influence development and chemoresistance in tumor cells [31].

Our findings revealed the diagnostic value of BidSi6 and BidEL isoforms. We studied the relationship between the expression of BidSi6 and BidEL isoforms and clinicopathological factors. However, no significant association was observed between BidSi6 and BidEL isoforms expression and the location of the adenomatous polyp (ascending colon, transverse colon, descending colon, sigmoid colon and rectum), age, and sex (male and female). Earlier studies showed the morphological and clinical features of colon and rectum cancers [32–34]. Colon and rectum cancers are different in many respects such as the rate and pattern of the mutations and inheritance [35]. On the contrary, this study showed that the polyps of the colon expressed a similar mRNA mold to those observed in the rectum.

In the second part of this study, we performed sequencing of BidSi6 in adenomatous polyp tissue, adjust non-polyp tissue from the same patients, and healthy colorectal tissue. It was revealed that there was 99% homology between BidSi6 sequences in a human adenomatous polyp tissue, adjust and the reference sequence (EU678292). The phylogenetic tree was constructed based on the sequence of idSi6 isoform readily separated adenomatous polyp tissue and adjust non-polyp tissue from healthy colorectal tissue and the reference sequence (EU678292).

**Conclusion**

Our study found significant upregulation of BidSi6 and BidEL isoforms in adenomatous polyp and its adjacent non-polyp tissues compared to that in the normal colon tissue. Alternative splicing events were shown to provide possible therapeutic targets for colorectal polyps. Our findings suggest that these two isoforms of Bid
may be a novel diagnostic biomarker for the identification of the adenomatous polyp. However, several studies are needed to know the prognostic value of BidSi6 and BidEL isoforms.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12920-022-01282-0.

Additional file 1. Location of the BidSi6 and BidEL amplified product in Bid isoform EL and Si6 mRNA sequences. In this study primers of BidSi6 and BidEL were designed according to GenBank reference sequences of these genes in NCBI with accession numbers EU678292 and AF250233 respectively. Forward and reverse primers were shown in bold and underlined. The size of the amplified product by BidSi6 and BidEL primers are 157bp and 138bp respectively.

Acknowledgements
The Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran is gratefully acknowledged.

Author contributions
FF participated in the study design and supervision, also did alignment of nucleotides and protein sequencing and did bioinformatics analysis, contributed to the interpretation of the data and the conclusion. E.N.M. collected the samples and supervision. F.S.K did lab work. F.F, F.S.K., and E.N.M. participated in data collection and evaluation and drafting. F.F. participated in the finalization of the manuscript and completed it. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The accession numbers of nucleotide and amino acid sequences related to BidSi6 isoform in adenomatous polyposis tissue that we submitted to GenBank are MG957990 (https://www.ncbi.nlm.nih.gov/nuccore/MG957990) and AVPS0013 (https://www.ncbi.nlm.nih.gov/protein/AVPS0013) respectively. Also, the accession numbers nucleotide and amino acid sequences related to BidEL isoform in healthy colorectal tissue submitted to GenBank are MH121045 (https://www.ncbi.nlm.nih.gov/nuccore/MH121045) and AWQ38328 (https://www.ncbi.nlm.nih.gov/protein/AWQ38328) respectively.

Declarations
Ethics approval and consent to participate
The Ethical code is IR.SBMU.RGILD.REC.1395.137. This research was approved by the Ethics Committee of Gastroenterology and Liver Disease Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. All protocols were carried out in accordance with clinical research guidelines and regulations of Gastroenterology and Liver Disease Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. All participants signed informed consent voluntarily prior to the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, P.O. Box: 193951495, Tehran, Iran.
2Department of Cancer, Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 27 September 2021 Accepted: 2 June 2022
Published online: 06 June 2022

References
1. Kim KM, Lee EJ, Ha S, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am Int J Colorectal Dis. 2011;35(9):1274-86. https://doi.org/10.1007/s00053-011-0938-2.
2. Zhang J, Deng Y, Zuo Y, et al. Analysis of colorectal cancer-associated alternative splicing based on transcriptome. DNA Cell Biol. 2020;39(1):16–24. https://doi.org/10.1089/dna.2019.5111.
3. Liu J, Shen Sh, Sun L, et al. Alternative splicing events implicated in carcinogenesis and prognosis of colorectal cancer. J Cancer. 2018;9(10):1754–64. https://doi.org/10.7150/jca.24569.
4. Berg KC, Ede PW, Eilertsen IA, et al. Multi-omics of 34 colorectal cancer cell lines—a resource for biomedical studies. Mol. cancer. 2017;6(1):116. https://doi.org/10.1186/s12943-017-0691-y.
5. Luo G, Saelens X, Gurn M, et al. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 2002;9(10):1031–42. https://doi.org/10.1038/sj.cdd.4401089.
6. Krajewska M, Zapata JM, Meinhold-Heerlein I, et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia. 2002;4(2):129–40. https://doi.org/10.1038/sj.neo.7800222.
7. Song G, Chen G, Lai PB. Bid stands at the crossroad of stress-response pathways. Curr Cancer Drug Targets. 2010;10(6):584–92. https://doi.org/10.2174/156800910791859515.
8. Green M, Hutchison GJ, Valentine HR, et al. Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix. Br J Cancer. 2005;92(3):449–58. https://doi.org/10.1038/sj.bjc.6602344.
9. Renshaw SA, Demspay CE, Barnes FA, et al. Three novel Bid proteins generated by alternative splicing of the human Bid gene. J Biol Chem. 2004;279(4):2846–55. https://doi.org/10.1074/jbc.M309769200.
10. Brinkman BMB. Splice variants as cancer biomarkers. Clin Biochem. 2004;37(7):584–94. https://doi.org/10.1016/j.clinbiochem.2004.05.015.
11. Kalniga Z, Zayakin P, Siliga K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Dev. 2005;19(4):342–7. https://doi.org/10.1016/j.gcd.2005.16.
12. Kim K, Lee HW, Lee EH, et al. Differential expression of HSP90 isoforms and their correlations with clinicopathologic factors in patients. Int J Cancer. 2019;12(3):978–86.
13. Dariya B, Aliya Sh, Merchant N, et al. Colorectal cancer biology, diagnosis, and therapeutic approaches. Crit Rev Oncog. 2020;25(2):71–94. https://doi.org/10.1615/CritRevOncog.2020035067.
14. Triantafillidis JK, Vagianos C, Malgarinos G. Colonoscopy in colorectal cancer screening: current aspects. Indian J Surg Oncol. 2015;6(3):237–50. https://doi.org/10.1007/s13193-015-0410-3.
15. Konstantinos Nikolouzakis TK, Vassilopoulou L, Fragiadaki P, et al. Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep. 2018;21:2455–72. https://doi.org/10.3892/or.2018.6330.
16. Buñanda L, Buñanda L, Cosme A, et al. Malignant colorectal polyps. World J Gastroenterol. 2010;16(25):3103–11. https://doi.org/10.3748/wjg.v16.i25.3103.
17. Chun-Wei Lee S, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22(9):976–86. https://doi.org/10.1038/nm.4165.
18. Munkley J, Livemore K, Rajan P, Elliott DJ. RNA splicing and splicing regulator changes in prostate cancer pathology. Hum Genet. 2017;136(9):1143–54. https://doi.org/10.1007/s00439-017-1702-9.
19. Wang BD, Lee NH. Aberrant RNA splicing in cancer and drug resistance. Cancers (Basel). 2018;10(1):458. https://doi.org/10.3390/cancers101010458.
20. Kastan BM. A BID for the pathway. Nature. 2005;437(7062):1103. https://doi.org/10.1038/37105.
22. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell. 2005;19(1):1–13. https://doi.org/10.1016/j.molcel.2005.05.026.

23. Sun YF, Yu LF, Saarma M, Timmusk T, Arumae U. Neuron-specific Bcl-2 homology 3 domain-only splice variant of Bak is anti-apoptotic in neurons, but pro-apoptotic in non-neuronal cells. J Biol Chem. 2001;276(19):16240–7. https://doi.org/10.1074/jbc.M010419200.

24. Chalfant CE, Rathman K, Pinkerman RL, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells dependence on protein phosphatase-1. J Biol Chem. 2002;277(15):12587–96. https://doi.org/10.1074/jbc.M112010200.

25. Yang L, Li N, Wang Ch, et al. Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J Biol Chem. 2004;279(12):11639–48. https://doi.org/10.1074/jbc.M312895200.

26. Marani M, Tenev T, Hancock D, et al. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol. 2002;22(11):3577–89. https://doi.org/10.1128/mcb.22.11.3577-3589.2002.

27. Mouhamad S, Besnault L, Thérèse Auffredou M, et al. B cell receptor-mediated apoptosis of human lymphocytes is associated with a new regulatory pathway of Bim isoform expression. J Immunol. 2004;172(4):2084–91. https://doi.org/10.4049/jimmunol.172.4.2084.

28. Cheng EH, Wei MC, Weler S, et al. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8(3):3577–89. https://doi.org/10.1016/s1097-2765(01)00320-3.

29. Kudla G, Montessuit S, Eskes R, et al. The destabilization of lipid membranes induced by the C-terminal fragment of caspase 8-cleaved bid is inhibited by the N-terminal fragment. J Biol Chem. 2000;275(30):22713–8. https://doi.org/10.1074/jbc.M003807200.

30. Goncharenko-Khaider N, Lane D, Matte L, et al. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene. 2010;29(40):5523–36. https://doi.org/10.1038/onc.2010.288.

31. de Necochea-Campion R, Shouse GP, Zhou Q, et al. Aberrant splicing and drug resistance in AML. J Hematol Oncol. 2016;9(1):85. https://doi.org/10.1186/s13045-016-0315-9.

32. Beart RW, Melton LJ 3rd, Maruta M, Dockerty MB, Frydenberg HB, O’Fallon WM. Trends in right and left-sided colon cancer. Dis Colon Rectum. 1983;26(6):393–8. https://doi.org/10.1007/bf02553382.

33. Bufl JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–88. https://doi.org/10.7326/0003-4819-113-10-779.

34. Lee YC, Lee YL, Chuang JP, Lee JCh. Differences in survival between colon and rectal cancer from SEER data. PLoS ONE. 2013;8(11): e78709. https://doi.org/10.1371/journal.pone.0078709.

35. van der Sijp MP, Bastiaannet E, Mesker WE, et al. Differences between colon and rectal cancer in complications, short-term survival and recurrences. Int J Colorectal Dis. 2016;31(10):1683–91. https://doi.org/10.1007/s00384-016-2633-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.